Nephrol Dial Transplant (2017) 32: 1415-1424 doi: 10.1093/ndt/gfx093 Advance Access publication 26 June 2017 incidence of acute rejection and graft survival would be an attractive treatment option. Calcineurin inhibitors (CNIs), including tacrolimus (TAC) and cyclosporine (CsA), have been used as the main immunosuppressive agents in kidney transplantation. They have reduced the incidence of acute rejection and increased short-term graft survival. However, long-term graft survival is relatively limited [1] . One possible cause is chronic allograft nephropathy (CAN) secondary to CNI nephrotoxicity [2] . Prevention and early treatment of CAN appear to be the best strategies to reduce late renal graft failure. Minimizing the dose of CNIs is one way to ameliorate CNI nephrotoxicity. Low-dose TAC plus mycophenolate mofetil (MMF) is an immunosuppressive regimen widely used nowadays to reduce CNI toxicity while preserving good renal function and a low incidence of acute rejection [3] .
Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (SRL) and everolimus (EVR), are potent immunosuppressive agents that impair lymphocyte activation and proliferation by inhibiting mTOR [4] . When SRL was introduced, it was expected to replace CNIs, since it could prevent CAN by inhibiting proliferation of vascular smooth muscle cells and did not seem to be nephrotoxic. However, post-transplant outcomes in terms of acute rejection, graft renal function, adverse events (AEs) or graft survival were not improved by SRL without CNIs in previous clinical trials [3, 5, 6] . Several studies demonstrated that TAC and SRL have synergistic immunosuppressive potency in preventing acute rejection [7] [8] [9] [10] [11] . However, most studies demonstrated that post-transplant outcomes of TAC with SRL were inferior to TAC with MMF [9] [10] [11] [12] [13] [14] [15] [16] [17] . These results were mainly attributable to high-dose SRL; it might cause synergistic nephrotoxicity with TAC and SRL-related side effects.
It has not been established whether low-dose SRL with extended-release tacrolimus (ER-TAC) can effectively prevent acute rejection, preserve renal function and be safe, when compared with conventional immunosuppressive regimens involving MMF and ER-TAC. In addition, few studies have demonstrated that low-dose SRL can facilitate minimizing TAC dosage while maintaining immunosuppressive potency.
This study was designed to compare the efficacy and safety of low-dose SRL versus MMF, in combination with a reduced dose of ER-TAC, when used as immunosuppressive agents for kidney transplant recipients.
M A T E R I A L S A N D M E T H O D S

Study design and participants
In this multicentre, open-label, randomized, non-inferiority trial, we enrolled 159 patients at seven transplant centres in Korea between 28 August 2012 and 23 February 2015. Eligible patients were aged 20 years or older and scheduled to receive a single-organ kidney transplant from either a living donor or deceased donor. Key exclusion criteria included recipients who had: received multi-organ or a kidney donated after cardiac death; anti-thymocyte globulin induction; the need for treatment with desensitization pre-transplantation; identical human lymphocyte antigen (HLA) matching between the donor and recipient; a cold ischaemic time of >30 h; recipient's leukocyte count <2500/lL, neutrophil count <1500/lL or platelet count <100 000/lL; recipient with hepatitis B or C virus infection; a history of any cancer, except successfully treated localized nonmelanoma skin cancer; and ABO-incompatible transplants.
The study was conducted in compliance with Good Clinical Practice Guidelines. The study protocol was approved by the independent institutional review board at each centre, and the procedures followed in the trial were in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to enrolment. This trial is registered with ClinicalTrial.gov (number NCT01680952).
Immunosuppression
After providing informed consent, patients enrolled in the study received induction treatment with basiliximab (SimulectV R ; Novartis, Basel, Switzerland), ER-TAC (Advagraf V R ; Astellas Pharma, Tokyo, Japan), SRL (Rapamune V R ; Pfizer, New York, NY, USA) and MMF. Basiliximab at 20 mg was given just before transplantation and 4 days after transplantation. For patients undergoing living donor kidney transplantation, ER-TAC was given orally at a dose of 0.2 mg/kg/day 2 days before transplantation and 0.1 mg/kg/day on the day before transplantation. For patients undergoing deceased donor kidney transplantation, one dose of ER-TAC at 0.1 mg/kg/day was given orally before transplantation. The ER-TAC dosing was then individually adjusted, with a goal of maintaining blood levels between 3 and 12 ng/mL within the first month after transplantation and between 3 and 8 ng/mL thereafter.
For the investigational group, 2 mg of SRL was begun within 24 h after reperfusion, and subsequent daily doses were individually adjusted with the goal of maintaining blood levels between 3 and 5 ng/mL. For the control group, 500 mg of MMF was started within 24 h after reperfusion as the first dose, then continued as from 1000 to 2000 mg/day. The 1000 mg dose was recommended; however, 2000 mg/day was administered at the discretion of the investigator. All patients received intraoperative and maintenance corticosteroids according to standard practice at the study centres.
Assessments
Study visits were conducted on the day before transplantation (baseline) and at 1 day, 2 weeks, and 1, 2, 3, 6, 9 and 12 months after transplantation. At each visit, we performed a complete physical examination and measured laboratory values related to kidney, liver and haematological function; lipid metabolism; proteinuria; and trough levels of immunosuppressive agents. Blood pressure, body weight and any other problems were documented during visits. Renal function assessment included the serum creatinine level and estimated glomerular filtration rate (eGFR), as determined by the Modification of Diet in Renal Disease (MDRD) formula [18] . Data were recorded and entered into electronic databases and re-evaluated by external monitors. The study team monitored and classified protocol deviations, which were then validated by the monitoring committee before locking the database. Cytomegalovirus (CMV) and BK virus (BKV) infection were evaluated by quantitative real-time polymerase chain reaction at 1, 6 and 12 months post-transplantation for CMV and at 1, 3, 6, 9 and 12 months post-transplantation for BKV.
Outcomes
The primary endpoint was the efficacy failure rate at 12 months post-transplantation, which was a composite of biopsy-proven acute rejection (BPAR), graft loss, patient death and patient loss to follow-up. The secondary endpoints were eGFR by MDRD, incidence of BPAR, overall survival and allograft survival.
Patients with clinical findings suggestive of acute rejection, such as elevation of serum creatinine >30% or 0.3 mg/dL from baseline, underwent biopsy before or within 48 h after initiating antirejection therapy. A single pathologist gathered the pathology reports from the participating centres and re-assessed the results using the Banff 1997 classification to confirm the diagnosis of BPAR [19] . Acute T-cell-mediated rejection was treated using a high dose of methylprednisolone with or without antithymocyte globulin, depending on the histologic grade and clinical course. Antibody-mediated rejection treatment consisted of plasma exchange, rituximab and intravenous immunoglobulin. Allograft loss was presumed to occur if the patient started dialysis and could not subsequently be removed from dialysis.
Safety was evaluated throughout the study by clinical assessment, including vital signs and laboratory analyses designed to determine the incidence of AEs, infections, malignancy and death. Safety assessments included the incidences of AEs, adverse drug reactions (ADRs) and serious adverse events (SAEs). An AE was defined as any unfavourable medical occurrence, including exacerbation of a pre-existing condition, in a patient in a clinical investigation who received a medicine. The event did not necessarily have a causal relationship with the treatment. The AE severity was graded as mild (usually transient in nature and generally not interfering with normal activities), moderate (sufficiently discomforting to interfere with normal activities) or severe (prevents normal activities). An ADR was defined as any AE except those considered 'not related' and 'maybe not related' to the study drug. An SAE was defined as any AE (sign, symptom or medical condition) meeting any of the following criteria: (i) was fatal or life-threatening, (ii) resulted in persistent or significant disability or incapacity; (iii) required hospitalization or prolongation of existing hospitalization; (iv) was a congenital anomaly or birth defect; or (v) was an important medical event that may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above. All AEs and SAEs were classified using terminology from the Medical Dictionary for Regulatory Activities.
Sample size, randomization and statistical analysis
In calculating the sample size, we assumed a 10% efficacy failure rate based on the results of a previous study. The predetermined non-inferiority margin d was an absolute 15% difference in efficacy failure rate (the rate in the ER-TAC with MMF group minus the rate in the ER-TAC with SRL group). Assuming a one-sided a of 0.025, power of 80% and 20% dropout rate, we calculated that it was necessary to enrol 79 patients in each group.
Eligible individuals were randomly assigned in a 1:1 ratio to the investigational (ER-TAC with SRL) or control group (ER-TAC with MMF). The randomization assignments were centrally released by an electronic case report form before transplantation. The randomization code was generated and performed using a block design stratified by each site. For randomization of the enrolled subjects, random seed with stratification factor as each research institution was generated. Block and block size were randomly assigned. The enrolled subjects, as well as their care providers, were blinded until the time of randomization. Every 6 months during the study, an independent Data Safety Monitoring Board examined the data related to the safety and accuracy of the study.
The safety population was defined as all randomly assigned patients who received at least one dose of a study drug, and the intention-to-treat (ITT) population was defined as all patients who received at least one dose of a study drug and underwent transplantation. Patients who were prematurely withdrawn from the study were followed for data collection whenever possible, and a last-observation-carried-forward method was used to account for missing data.
Data are expressed as mean 6 standard deviation for continuous variables and number (proportion) for categorical variables. For other analyses, two-sample comparisons were performed with the use of Student's t-test for continuous variables and chi-square or Fisher's exact test for categorical variables. Time to BPAR, allograft loss and death were analysed with the use of the Kaplan-Meier method, and group differences were assessed by log-rank. All statistical analyses were performed using the SAS statistical software 9.4 (SAS Institute). A P-value <0.05 was considered statistically significant.
R E S U L T S Patients
A total of 158 patients from seven centres in Korea underwent randomization during the study period. Figure 1 shows the study profile with respect to patient enrolment and outcomes. Of the 158 randomized patients, 151 (76 in the investigational group and 75 in the control group) were provided with at least one dose of study drug and underwent transplantation; they comprised the ITT population. A total of 122 patients (59 in the investigational group and 63 in the control group) completed the study follow-up procedures, as well as the study drug treatment; they comprised the per-protocol (PP) population.
The rate of drop out from the assigned treatment was 16.0% in the control group and 22.3% in the investigational group (P ¼ 0.41). The protocol violation rates were 12% (9/75) in the control group and 6.6% (5/76) in the investigational group (P ¼0.28). The rates of AEs leading to discontinuation were 2.7% (2/75) in the control group and 10.5% (8/76) in the investigational group (P ¼0.10). Reasons for discontinuing SRL due to AEs included oedema (n ¼ 2), proteinuria (n ¼ 1), serum creatinine elevation (n ¼ 1), pneumonia (n ¼ 1), enteritis (n ¼ 1), nausea (n ¼ 1) and diabetes mellitus (n ¼ 1). Reasons for
There were no significant differences in age, gender, cause of end-stage renal disease (ESRD), type of donor, donor age or retransplantation between groups. The degrees of mismatch for both HLA-B and HLA-DR were higher in the control group than in the investigational group; however, there were no statistically significant differences in the number of HLA-A, -B and -DR mismatches between groups (P ¼ 0.19; Table 1 ).
Target trough levels for TAC and SRL were generally met ( Figure 2 ). Mean TAC trough levels were similar between groups except at 2, 4 and 12 weeks post-transplantation, when the trough levels were lower in the investigational group than in the control group (5.9 6 3.4 versus 6.6 6 3.7 ng/mL at 2 weeks, 6.2 6 3.1 versus 7.2 6 4.2 ng/mL at 4 weeks, and 5.6 6 2.0 versus 6.3 6 2.1 ng/mL at 12 weeks; P ¼ 0.09, 0.09 and 0.001, respectively). Mean SRL trough levels were 4.7 6 1.7, 5.0 6 2.0 and 4.9 6 2.2 ng/mL at 1, 3 and 12 months, respectively. Mean doses of MMF were 1056 6 199, 1011 6 168 and 1000 6 151 mg at 1, 3 and 12 months, respectively.
Outcomes and endpoints
In the ITT population, the efficacy failure rate was 6.6% in the investigational group and 13.3% in the control group. In the investigational group, four patients were diagnosed with BPAR and one patient died with a functioning graft (the cause of death was intracerebral haemorrhage). Ten patients developed BPAR in the control group. The absolute difference in efficacy failure was 6.8% [95% confidence interval (CI), À2.8% to 16.3%]. The lower limit of the CI for the absolute difference (2.75%) was higher than the À15% non-inferiority margin specified in the protocol (Figure 3 ). In the PP population, the absolute difference in efficacy failure was 7.7% (95% CI, À1.3% to 16.8%), which also achieved the primary endpoint of non-inferiority. Figure 4 shows that the eGFR was generally similar between groups at each visit. Only at 2 weeks after transplantation in the PP population was the eGFR higher in the investigational group than in the control group (66.4 versus 58.6 mL/min/1.73 m 2 , P ¼ 0.03). The mean eGFR at 12 months post-transplantation was 52.4 mL/min/1.73 m 2 in the investigational group and 53.2 mL/min/1.73 m 2 in the control group (P ¼ 0.76). At 12 months after kidney transplantation in the ITT population, the rate of BPAR was lower in the investigational group than in the control group. However, the difference between groups was not statistically significant, even when borderline changes were included (P ¼ 0.09, excluding borderline values and P ¼ 0.28, including borderline values). Detailed pathologic findings are described in Table 2 . There was also no statistically significant difference in cumulative probability of BPAR between groups (P ¼ 0.12; Figure 5A ).
Only one patient died with a functioning graft in the investigational group, and no graft failure occurred in either group. There were no significant differences in patient survival (P ¼ 0.32) or allograft survival (P ¼ 0.32) between the two groups ( Figure 5B ).
Safety
Among the 151 patients in the safety population, 147 (97.4%) exhibited at least one AE (Table 3) . Overall, 74 (97.4%) of the 76 patients in the investigational group and 73 (97.3%) of the 75 patients in the control group reported AEs during the study period (P > 0.99). The incidence of ADRs was similar between groups: 63.2% in the investigational group and 62.7% in the control group (P ¼ 0.95). The incidences of SAEs and severe AEs also did not differ significantly between groups (P ¼ 0.37 and P ¼ 0.69, respectively). The incidence of AEs leading to study drug discontinuation and the incidence of wound complications were higher in the investigational group than in the control group; however, the differences did not achieve statistical significance (10.5% versus 2.7%, P ¼ 0.10, for both comparisons). The CMV infection rate was significantly lower in the investigational group than in the control group (1.3% versus 9.3%, P ¼ 0.03). BKV infection rate was also lower in the investigational group than in control group, although the difference was not statistically significant (5.3% versus 12.0%, P ¼ 0.14).
The most frequently reported AEs were elevation of liver enzymes (27.6% in the investigational group and 14.7% in the control group, P ¼ 0.07), upper respiratory infection (23.7% in the investigational group and 28.0% in the control group, P ¼ 0.58), diarrhoea (22.4% in the investigational group and Differences in efficacy failure rates. Differences in efficacy failure rates and the corresponding 95% CIs are shown. The difference represents the efficacy failure rate in the ER-TAC with MMF group minus the rate in the ER-TAC with SRL group. Efficacy failure is a composite of BPAR, graft loss, patient death and patient loss to follow-up. The predetermined non-inferiority margin d was an absolute 15% difference (represented by the grey zone). (18.4% in the investigational group and 14.7% in the control group, P ¼ 0.66) and acne (15.8% in the investigational group and 9.3% in control group, P ¼ 0.33). The incidence of AEs by system organ class was generally similar between the two groups. Most AEs were mild (67.6% in the investigational group and 71.6% in the control group, P ¼ 0.42). Detailed data regarding the AEs are shown in Table 3 .
D I S C U S S I O N
This trial showed that low-dose SRL in combination with ER-TAC was non-inferior to MMF with ER-TAC in terms of efficacy and safety when used as the immunosuppressant regime in patients undergoing kidney transplantation. Previous retrospective observational studies reported that TAC with SRL was associated with worse graft survival, patient survival or graft renal function in kidney transplantation, compared with TAC with MMF [16, 17] . Several randomized clinical trials evaluated the efficacy and safety of TAC with or without corticosteroid in combination with SRL versus MMF [9] [10] [11] [12] [13] [14] [15] [20] [21] [22] . These studies used various maintenance blood trough levels of TAC and SRL. In most of the studies, anti-CD25 antibody was used as an induction therapy [10] [11] [12] [13] [14] [15] 22] . Most previous results favoured TAC with MMF over TAC with SRL in terms of graft renal function, graft survival, acute rejection, drug discontinuation or AEs [9] [10] [11] [12] [13] [14] [15] [16] [17] . In contrast to these results, our study found noninferior efficacy and safety of ER-TAC with low-dose SRL compared with ER-TAC with MMF.
A few previous randomized controlled trials assessed the use of SRL in combination with reduced-exposure TAC versus MMF in combination with TAC [10] [11] [12] . MMF combined with TAC provided numerically or significantly better posttransplant outcomes in terms of patient and graft survival, BPAR and graft renal function. The maintenance blood trough levels of SRL were higher than the levels used in our study. As shown in the 'Results' section, the mean trough level of SRL was well maintained around 5 ng/mL (within the therapeutic range) throughout the study period. Reduced-exposure ER-TAC was also well maintained in both groups. The mean trough levels of TAC were similar to those in the Symphony study [3] .
The distinction between our immunosuppressive strategy and those used in previous studies was that we used low doses for both SRL and ER-TAC. The combination of standard doses 
Categorical variables are presented as number (%), and their P-values were calculated with the Fisher's exact test. AMR, antibody-mediated rejection; TCMR, T-cell-mediated rejection. Continuous variables are expressed as mean 6standard deviation, and their P-values were calculated with the t-test. Categorical variables are expressed as number (%), and their P-values were calculated with chi-square or Fisher's exact tests.
of SRL and TAC may potentiate CNI nephrotoxicity, leading to decreasing graft function and CAN [11, 17] . This can be alleviated by using low doses of SRL and TAC to promote preservation of renal function. Graft renal function was comparable in the SRL group and MMF group in both the ITT and PP populations. This result suggests that TAC minimization facilitated by using low-dose SRL can reduce CNI nephrotoxicity and preserve renal function as well as reduced-exposure TAC with MMF. According to the Symphony study, a regimen containing reduced-exposure TAC with MMF, steroid and daclizumab provided better renal function than daclizumab induction plus reduced-exposure CsA-or reduced-exposure SRL-containing regimens, or a regimen containing standard-exposure CsA without daclizumab induction [3] .
In terms of BPAR, our study showed a trend favouring the SRL group (5.3%) compared with the MMF group (13.3%), although this difference did not reach statistical significance. The severity of BPAR was not different between the two groups. The trend towards higher incidence of BPAR in the MMF group may be attributed to demographic differences. The number of HLA mismatching, proportion of deceased donor and rate of re-transplantation in the MMF group were higher than in the SRL group, although these differences were not statistically significant. The dose of MMF was determined based on our clinical data. A Low dose of MMF (1000 mg/day) might decrease the infection rate and gastrointestinal AEs without increasing the incidence of rejection or graft loss. A recent study performed in Korean recipients holds that a low dose of MMF can be efficacious and safe [23] . In the Symphony trial, the rate of BPAR excluding borderline values was 12.3% at 12 months after transplantation in the MMF (2000 mg/day) group. This result is comparable to that of our study [3] . According to our result, low-dose SRL in combination with ER-TAC can be a potent and efficacious immunosuppressive strategy in preventing acute rejection in kidney transplant recipients with low immunological risk.
SRL can produce side effects that differ from those of CNIs, such as wound complications, lymphocele, pneumonitis and proteinuria [24] [25] [26] . SRL-induced side effects may be dose dependent. Previous randomized trials indicated that premature drug discontinuation rates of regimens including SRL were significantly higher than those of regimens including MMF [9, 10, 12, 14, 15, 21] . Our data demonstrated that the rate of drug discontinuation due to AEs was higher in the SRL group (10.5%) than in the MMF group (2.7%), although the rate was not statistically significant. Nonetheless, the rate of discontinuing SRL due to AEs in our study was low compared with those of previous studies. In terms of the incidence of wound complication, it is low compared with those of previous studies. Although the incidence of wound complications was numerically higher in the SRL group (10.5%) than in the MMF group (2.7%), the severities of these cases were almost all mild grade (87.5%) and all wound complications was resolved without problems. The incidence of wound complications was numerically higher in the SRL group (10.5%) than in the MMF group (2.7%). This was relatively low compared with previous studies that used higher dose of SRL [24] . These findings suggest that using low doses of SRL can reduce the side effects associated with SRL and enhance tolerability of the drug. SRL has several advantages, including antiproliferative effects on vascular smooth muscle cells, antiviral effects against CMV and BKV, and anticancer effects [27] [28] [29] [30] [31] . Our study demonstrated that the SRL group had a significantly reduced incidence of CMV infection compared with the MMF group. SRL has also been reported to reduce the risk of BKV infection [30] . In the current study, the incidence of BKV infection was lower in the SRL group (5.3%) than in the MMF group (12.0%), but the difference was not statistically significant. Both SRL and ER-TAC are once-daily medications. Although we did not evaluate adherence to the immunosuppressive regimes used in this study, this convenient dosing schedule for SRL with ER-TAC may enhance drug adherence and patient satisfaction.
This study has a limitation in terms of follow-up duration, as it followed patients for only 12 months post-transplantation. Therefore, future studies are necessary to evaluate longer term efficacy and safety.
Our findings suggest that low-dose SRL in combination with ER-TAC as immunosuppresive therapy for renal transplant recipients can be effective in preventing acute rejection, while being safe and preserving graft renal function. Lowdose SRL allows minimization of TAC dosage, thereby maintaining good renal function and a low incidence of acute rejection, comparable to the outcomes observed with MMF plus reduced-exposure TAC.
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